 DEER PARK, Ill., Jan. 14, 2021 GLOBE NEWSWIRE -- Eton Pharmaceuticals, Inc. Nasdaq: ETON, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI SPRINKLE from Diurnal Group plc LSE AIM: DNL. Eton Pharmaceuticals currently commercializes ALKINDI SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency AI in children under 17 years of age. 